192 related articles for article (PubMed ID: 29878616)
1. Prevalence of antinuclear antibodies in hidradenitis suppurativa.
Mulani S; McNish S; Jones D; Shanmugam VK
Int J Rheum Dis; 2018 May; 21(5):1018-1022. PubMed ID: 29878616
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.
Boortalary T; Misra K; McNish S; Jones D; Shanmugam VK
J Dermatolog Treat; 2018 Sep; 29(6):637-640. PubMed ID: 29325465
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
5. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications.
Ellis A; Khanna U; Galadari A; Fernandez AP
J Am Acad Dermatol; 2020 Jul; 83(1):246-248. PubMed ID: 31940465
[No Abstract] [Full Text] [Related]
6. Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
Dumont LM; Landman C; Sokol H; Beaugerie L; Cosnes J; Seksik P; Guégan S;
Aliment Pharmacol Ther; 2020 Jul; 52(2):303-310. PubMed ID: 32525586
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
[No Abstract] [Full Text] [Related]
8. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
Kanni T; Zenker O; Habel M; Riedemann N; Giamarellos-Bourboulis EJ
Br J Dermatol; 2018 Aug; 179(2):413-419. PubMed ID: 29405257
[TBL] [Abstract][Full Text] [Related]
9. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
10. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma (IFN-γ) is Elevated in Wound Exudate from Hidradenitis Suppurativa.
Banerjee A; McNish S; Shanmugam VK
Immunol Invest; 2017 Feb; 46(2):149-158. PubMed ID: 27819528
[TBL] [Abstract][Full Text] [Related]
12. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa.
Savva A; Kanni T; Damoraki G; Kotsaki A; Giatrakou S; Grech I; Katoulis A; Papadavid E; Giamarellos-Bourboulis EJ
Br J Dermatol; 2013 Feb; 168(2):311-7. PubMed ID: 23106544
[TBL] [Abstract][Full Text] [Related]
13. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
14. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
16. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
[TBL] [Abstract][Full Text] [Related]
17. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
Hessam S; Sand M; Gambichler T; Bechara FG
J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
[TBL] [Abstract][Full Text] [Related]
18. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
19. Hidradenitis suppurativa managed with adalimumab.
Yamauchi PS; Mau N
J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
